Indraprastha Medical Corporation Intrinsic Value
Indraprastha Medical Corporation intrinsic value. Indraprastha Medical Corporation (INDRAMEDCO) median intrinsic value is ₹333.91 from 10 valuation models (range ₹160–₹460), vs current price ₹360.35 — -7.3% downside (Trading Near Calculated Value), margin of safety -7.9%. For current market price and key ratios, visit Indraprastha Medical Corporati share price today.
INDRAMEDCO Valuation Methods Summary — DCF, Graham Number & P/E
Indraprastha Medical Corporation intrinsic value across 10 models vs current price ₹360.35 — upside/downside and value range per method. Analyse INDRAMEDCO shareholder distribution to track promoter, FII and institutional holdings.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹459.80 | ₹367.84 - ₹551.76 | +27.6% | EPS: ₹20.90, Sector P/E: 22x |
| Book Value Method | asset | ₹160.87 | ₹144.78 - ₹176.96 | -55.4% | Book Value/Share: ₹80.43, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹345.00 | ₹310.50 - ₹379.50 | -4.3% | Revenue/Share: ₹172.50, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹338.04 | ₹304.24 - ₹371.84 | -6.2% | EBITDA: ₹311.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹246.57 | ₹197.26 - ₹295.88 | -31.6% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹334.40 | ₹300.96 - ₹367.84 | -7.2% | EPS Growth: 20.0%, Fair P/E: 16.0x |
| Growth Adjusted P/E | growth | ₹328.19 | ₹295.37 - ₹361.01 | -8.9% | Revenue Growth: 9.4%, Adj P/E: 15.7x |
| ROE Based Valuation | profitability | ₹333.91 | ₹300.52 - ₹367.30 | -7.3% | ROE: 25.9%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹160.87 | ₹144.78 - ₹176.96 | -55.4% | EPS: ₹20.90, BVPS: ₹80.43 |
| Dividend Yield Method | dividend | ₹160.00 | ₹144.00 - ₹176.00 | -55.6% | DPS: ₹4.00, Target Yield: 2.5% |
INDRAMEDCO Intrinsic Value vs Market Price — All Valuation Models
Indraprastha Medical Corporation fair value range ₹160–₹460 vs current market price ₹360.35 across 10 valuation models. Browse INDRAMEDCO annual financials for revenue, profit, balance sheet and cash flow data.
INDRAMEDCO Intrinsic Value Analysis — Undervalued or Overvalued?
Indraprastha Medical Corporation median intrinsic value ₹333.91, current price ₹360.35 — Trading Near Calculated Value by 7.3%, margin of safety -7.9%.
What is the intrinsic value of INDRAMEDCO?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Indraprastha Medical Corporation (INDRAMEDCO) is ₹333.91 (median value). With the current market price of ₹360.35, this represents a -7.3% variance from our estimated fair value.
The valuation range spans from ₹160.00 to ₹459.80, indicating ₹160.00 - ₹459.80.
Is INDRAMEDCO undervalued or overvalued?
Based on our multi-method analysis, Indraprastha Medical Corporation (INDRAMEDCO) appears to be trading near calculated value by approximately 7.3%.
INDRAMEDCO Financial Health — Key Ratios vs Industry Benchmarks
Indraprastha Medical Corporation financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 25.9% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 18.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.60x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
INDRAMEDCO Cash Flow Quality — Operating & Free Cash Flow
Indraprastha Medical Corporation operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹167 Cr | ₹78 Cr | Positive Free Cash Flow | 7/10 |
| March 2025 | ₹157 Cr | ₹102 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹200 Cr | ₹121 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹145 Cr | ₹91 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹94 Cr | ₹57 Cr | Positive Free Cash Flow | 8/10 |